Abeona Therapeutics (ABEO) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, losing 10.5% versus a loss of 17.0%. Over five years, VNDA leads with a -75.4% price change compared with -78.2% for ABEO. Abeona Therapeutics is the larger company by market cap ($282.8 million vs $274.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | VNDA |
|---|---|---|
| Share price | $4.95 | $4.55 |
| Market cap | $282.83M | $274.86M |
| 1-day change | -0.28% | +0.35% |
| YTD return | -5.88% | -48.64% |
| 1-year return | -10.47% | -17.03% |
| 5-year return | -78.20% | -75.39% |
| Forward P/E | — | 22.73 |
| EPS (TTM) | $-1.18 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $9.94 |
| 52-week low | $4.00 | $4.27 |
| Distance from 52-week high | -35.35% | -54.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +281.72% | +158.47% |
| Average volume | 1.39M | 974.13K |
| Shares outstanding | 57.18M | 60.46M |
| Employees | 226 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
ABEO vs VNDA FAQ
Which is bigger, Abeona Therapeutics or Vanda Pharmaceuticals?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $282.83M compared with $274.86M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, ABEO or VNDA?
ABEO returned -10.47% over the past 12 months, compared with -17.03% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.